Successful immuno-oncology cancer treatment generally requires combination therapy, and oncolytic viruses have emerged as a safe and effective complement. OncoMyx is developing best-in-class (multi-armed, systemically-delivered, precision medicine) oncolytic immunotherapies based upon the myxoma virus (MYXV) platform, and we have demonstrated combinatorial efficacy (tumor growth inhibition) when dosed with various checkpoint inhibitors in multiple animal models.
Our company includes the industry’s most experienced oncolytic virus (OV) development team, and CEO Steve Potts was previously an executive at Ignyta (acquired by Roche for $1.7B). OncoMyx raised a $25 million series A in June 2019 to advance our lead preclinical program to IND, and among our investors are BIVF (exited OV investment ViraTx for $244M at preclinical stage in 2018) and Jonathan Lim (Ignyta founding CEO). With additional funding, OncoMyx is seeking to broaden our therapeutic pipeline and advance into clinical development.
On August 4th at 4pm PT, OncoMyx will provide discuss the company’s oncolytic immunotherapies at Inaugural LifeSci Partners Private Company Virtual Summer Symposium.